bi 765063
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 16, 2019 (NCT03990233)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05446129 | Phase 1 | Sep 27, 2022 | Boehringer Ingelheim |
| NCT05249426 | Phase 1 | Feb 25, 2022 | Boehringer Ingelheim |
| NCT05068102 | Phase 1 | Nov 16, 2021 | Boehringer Ingelheim |
| NCT04653142 | Phase 1 | Dec 14, 2020 | Boehringer Ingelheim |
| NCT03990233 | Phase 1 | Apr 16, 2019 | Boehringer Ingelheim, OSE Immunotherapeutics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 5 | 4 | 1 | 2019 |
| OSE Immunotherapeutics | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1